Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02472561 · ClinicalTrials.gov registry record · NA
Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT02472561: Completed NA study, sponsored by Duke University.
NCT02472561 is a NA study that has completed, run by Duke University. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02472561, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the effects that a three month lifestyle-based mobile health (mHealth) peripheral artery disease (PAD) prevention program will have on improving physical activity, fitness, important PAD risk factors and quality of life (QOL) in patients with PAD. By testing a novel mHealth intervention focused on lifestyle modification, this trial will address a critical evidence gap in the care of PAD patients. PAD patients are not eligible for cardiac rehabilitation and therefore struggle with unhealthy lifestyles, and these patients currently have no lifestyle-based care strategies to help them. The results of this study have the potential to lead to new sustainable and resource-efficient, lifestyle-based preventive care strategies for patients with stable PAD.
Primary Outcome
peak VO2 mL/kg/min
Interventions
- OTHER Fitbit Physical Activity Monitor
- OTHER mHealth Glucometer
- OTHER mHealth Blood Pressure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-11-07 |
| Phase | NA |
What the finished NCT02472561 record still lists
NCT02472561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Fitbit Physical Activity Monitor is the first listed.
NCT02472561 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02472561 about?
NCT02472561 is a clinical study titled "Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)". The purpose of this study is to understand the effects that a three month lifestyle-based mobile health (mHealth) peripheral artery disease (PAD) prevention program will have on improving physical activity, fitness, important PAD risk factors and quality of life (QOL) in patients with PAD. By testi...
What is the current status of trial NCT02472561?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2015-07. Estimated completion is 2017-11-07.
What interventions are being tested in trial NCT02472561?
The interventions under investigation include: Fitbit Physical Activity Monitor (OTHER), mHealth Glucometer (OTHER), mHealth Blood Pressure (OTHER).
Who is sponsoring clinical trial NCT02472561?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02472561's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia